top of page

Human antibody against COVID-19 ready for clinical trials

YUMAB spin-off CORAT Therapeutics announced that the first major batch of its SARS-CoV-2 blocking antibody COR-101 has been produced and is now available for clinical trials. COR-101 is a fully human antibody, which efficiently blocks the cell entry of SARS-CoV-2 thereby preventing the proliferation of corona viruses.

Photo: Fraunhofer ITEM, Prof. Holger Ziehr

CORAT Therapeutics CEO Dr. Andreas Herrmann today announced the completion

of the production campaign of the first major batch of COR-101, which is now

available for clinical trials. COR-101 is a fully human antibody developed in

Braunschweig, Germany, which efficiently blocks the cell entry of SARS-CoV-2 and

thus prevents the proliferation of corona viruses. As COR-101 attacks the virus

directly, its first clinical application will focus on helping already infected patients, as

this is the most urgent medical need in the pandemic. However, it is expected that

COR-101 will also protect the non-infected - this will be tested in a second step.

Human antibodies are molecules that our own body produces to fight infections.

COR-101 is one of these antibodies. CORAT Therapeutics produces it in large

quantities using biotechnological methods. By directly neutralising the corona

viruses, it is also intended to help patients who cannot produce their own antibodies

in time.

Dr. Andreas Herrmann adds: "We are extremely happy and would like to thank

everyone who has contributed to making this happen so quickly. In view of the rapidly

increasing number of acute cases, CORAT wants to create a possibility for direct

treatment of COVID-19 patients in order to help all those who are already infected or

for whom the vaccination does not work. We hope that the clinical trials can now start

very soon".

The production process was based on stable expressing CHO cell pools. This new

path of bioprocess development was taken for the first time and allowed the

manufacturing of the clinical test material in a much shorter time than with

conventional antibody production methods. Prof. Holger Ziehr, Head of the

Pharmaceutical Biotechnology Division at the Fraunhofer ITEM in Braunschweig,

who is in charge of the production of the clinical antibody, comments: "Thanks to the

excellent cooperation between all partners and the regulatory authorities, we were

able to develop a novel and innovative production process that saved many months.

What we have learned here will certainly also inspire more efficient drug

development in the future".

The start of clinical trials with COR-101 is planned for early next year.


bottom of page